| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, U.K.—Horizon Discovery Group plc announced late last year the addition of a predesigned synthetic single guide RNA (sgRNA) option to its product range. The sgRNAs, available individually or as library collections, expand the company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful CRISPR gene editing.
Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts in even complex, difficult-to-edit cell types and experimental models, the company says. The synthetic sgRNAs have been designed using Horizon’s proprietary algorithm to maximize the likelihood of functionally knocking out genes of interest while minimizing off-target effects.
 
These predesigned synthetic sgRNAs, when paired with Cas9 mRNA or Cas9 protein, reportedly allow researchers to perform DNA-free gene editing in a new one-part format thereby streamlining their gene editing workflows, without the potential for nuclease or guide integration into the cell’s genome. They can also be paired with expressed formats such as Cas9 integrated cell lines, which is ideal for high-throughput library screening.
 
The company will continue to provide its CRISPR design tool, where customers can design custom guide RNA to edit a specific region within a DNA transcript or input their own guide RNA target sequence to generate ready-to-use sgRNA.
 
“Previously, Horizon had only offered synthetic sgRNAs through the CRISPR Design tool. Providing predesigned synthetic sgRNAs guarantees editing the gene of interest, and gives researchers a more convenient option for gene knockout experiments,” said Ryan Donnelly, product manager at Horizon Discovery. “For those that require site-specific editing, are working in unique organisms, or use alternative editing nucleases; our CRISPR design tool is still available.”

Related Topics

Published In

Volume 16 - Issue 1 | January 2020

January 2020

January 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue